SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection

DRUG3 trials

Sponsors

Advanced Accelerator Applications, Camurus AB, Novartis Pharma AG

Conditions

Gastroenteropancreatic neuroendocrine tumor (GEP-NET)Patients with somatostatin receptor positiveadvanced GEP NETsgastroenteropancreatic neuroendocrine tumorswell-differentiated G2 and G3

Phase 3

A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors

Active, not recruitingCTIS2023-508723-12-00

Camurus ABgastroenteropancreatic neuroendocrine tumors

Start: 2021-09-27Target: 234Updated: 2025-10-28

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET (NETTER-2)

Active, not recruitingCTIS2023-507443-10-00

Advanced Accelerator Applicationsadvanced GEP NETs, Patients with somatostatin receptor positive, well-differentiated G2 and G3

Start: 2019-11-04Target: 90Updated: 2025-11-19

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3)

RecruitingCTIS2024-518325-15-00

Novartis Pharma AGGastroenteropancreatic neuroendocrine tumor (GEP-NET)

Start: 2025-09-08Target: 99Updated: 2025-12-09